Alder’s epti to benefit from SubQ profile, says Piper Jaffray

Piper Jaffray analyst Danielle Brill kept her Overweight rating and $28 price target on Alder Biopharmaceuticals following her meeting with its CEO Robert Azelby. The analyst says that the discussion of the recent launch of competitor SubQ anti-CGRP mAbs for migraine prevention raised the profile of its eptinezumab, noting that “given epti’s rapid onset of effect and deep magnitude of response, the company believes there will be demand” for epti. Brill still sees the program’s BLA submission on track for Q1 of 2019 with the potential launch coming in Q1 of 2020.
https://thefly.com/landingPageNews.php?id=2829489